Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Core Viewpoint - Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, which will enhance its portfolio in immunology and rare-disease medicines [1] Company Summary - The acquisition of Apellis Pharmaceuticals represents a strategic move for Biogen to expand its offerings in the immunology sector [1] - The deal is valued at around $5.6 billion, indicating a significant investment by Biogen in the rare-disease market [1] Industry Summary - This acquisition highlights the growing trend in the pharmaceutical industry towards consolidating resources to strengthen capabilities in specialized therapeutic areas such as immunology and rare diseases [1]